Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,320 recruiting studies in this area right now.
By phase
- Not applicable9,604
- Phase 24,428
- Phase 12,683
- Phase 1/Phase 21,650
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer646
- Cancer638
- Colorectal Cancer479
- Lung Cancer421
- Ovarian Cancer342
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma257
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer228
- Cervical Cancer226
- Endometrial Cancer214
- Advanced Solid Tumors207
- Esophageal Cancer192
Leading sponsors
- M.D. Anderson Cancer Center455
- Fudan University305
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital128
Where studies are running
- California1,397
- Texas632
- Arizona508
- Florida436
- Alabama430
- New York405
- Massachusetts340
- Maryland331
- New Jersey275
- Pennsylvania235
Recruiting studies20,320 total
- NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06650748Enrolling by invitationPhase 2
A study of hormone therapy with or without a targeted drug for breast cancer
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
BeijingAges 18–70 - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
Birmingham, AlabamaAges 18 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT05304988Recruiting
Exercise therapy program for teens with cancer
This study is developing and testing (validating) an “exercise-focused” therapy for teenagers with cancer. It may help researchers see whether this approach is practical and beneficial, especially for teens’ communication and activity support.
Hong Kong, Hong Kong,ChinaAges 13–18 - NCT05802121RecruitingEarly Phase 1
Testing a gut bacteria supplement side effects during prostate hormone therapy
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
London, OntarioAges 18 years+ - NCT06258642Recruiting
Irinotecan liposome plus anlotinib for SCLC after first chemo
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06641791RecruitingPhase 3
Comparing two radiation approaches for advanced head and neck cancer
This trial compares two types of radiation therapy to relieve symptoms from advanced head and neck cancer that cannot be cured. One is a shorter, more precise treatment (SBRT), and the other is standard radiation. The goal is to see which better improves quality of life and reduces side effects.
Calgary, AlbertaAges 18 years+ - NCT06644846Recruiting
Spaced radiation for gynecologic cancers
This trial tests a special type of radiation that is given in small, spaced-out beams to treat gynecologic cancers (like cervical or uterine cancer). It is for patients who cannot get standard internal radiation (brachytherapy) because of unusual anatomy, large tumors, a narrow vagina, or anesthesia risks.
Navi Mumbai, MaharashtraAges 18–70 - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Birmingham, AlabamaAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06638502RecruitingPhase 1/Phase 2
Testing HRX215 for liver recovery after surgery
This trial tests a drug called HRX215 to see if it is safe and helps the liver recover after surgery to remove colon cancer tumors that have spread to the liver. It is for people who are having either a minor or major liver resection and have a low risk of liver failure.
Baltimore, MarylandAges 18–75 - NCT06644300RecruitingPhase 1
Study of BM230 for advanced solid tumors with HER2
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Brisbane, QueenslandAges 18 years+ - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT06640413RecruitingPhase 1
Study of radioactive treatment for FAP-positive advanced tumors
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
Bergamo, BergamoAges 18 years+ - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
Boston, MassachusettsAges 18 years+ - NCT06639256RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug called HY07121 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
JinanAges 18–80 - NCT06641609RecruitingPhase 1
Study of CFT8919 for advanced NSCLC with EGFR L858R mutation
This trial tests a new drug, CFT8919, for people with a specific type of advanced lung cancer (non-small cell lung cancer with an EGFR L858R mutation) that has stopped responding to other treatments. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT06639828RecruitingPhase 4
Safety study of Sonazoid for liver ultrasound in children
This trial tests a contrast agent called Sonazoid, which is used during an ultrasound to get clearer pictures of the liver. It is for children and teens who have one or more spots in the liver that need to be checked. The goal is to see if Sonazoid is safe and works well for children.
MünchenAges Up to 18 years - NCT06643884RecruitingPhase 2
Study of eye treatment for cancer that has spread to the eye
This trial tests a new way to treat cancer that has spread to the back of the eye (choroid). The treatment is given directly into the eye, which may help control the tumor and preserve vision.
Palo Alto, CaliforniaAges 18 years+ - NCT06640361RecruitingPhase 3
Study of olverembatinib for a rare type of GIST
This trial tests a new drug, olverembatinib, for GIST that lacks the SDH enzyme and has gotten worse after at least one prior treatment. It aims to see if the drug can stop or shrink the tumor.
Guangzhou, GuangdongAges 12 years+ - NCT06634849RecruitingPhase 1/Phase 2
Study of a new drug (PTT-4256) for advanced solid tumors
This trial tests a new drug called PTT-4256 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it helps shrink or control the cancer.
Blacktown, New South WalesAges 18 years+ - NCT06641908RecruitingPhase 1
Anti-GD2 drug M3554 for advanced solid tumors
This trial tests a new drug called M3554 that targets a protein (GD2) found on some cancer cells. It is for people whose cancer has not responded to standard treatments, including certain sarcomas and glioblastoma. The goal is to see if M3554 can shrink or stop the cancer.
Boston, MassachusettsAges 18 years+ - NCT06641414RecruitingPhase 3
Lisaftoclax with azacytidine for higher-risk myelodysplastic syndrome
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
Birmingham, AlabamaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,320 recruiting oncology studies from the U.S. registry right now, out of 31,393 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.